A subscription to JoVE is required to view this content. Sign in or start your free trial.
This article describes the generation of a complex, multi-cellular airway barrier model composed of induced pluripotent stem cell (iPSC)-derived lung epithelium, mesenchyme, endothelial cells, and macrophages in an air-liquid interface culture.
Human lung tissue is composed of an interconnected network of epithelium, mesenchyme, endothelium, and immune cells from the upper airway of the nasopharynx to the smallest alveolar sac. Interactions between these cells are crucial in lung development and disease, acting as a barrier against harmful chemicals and pathogens. Current in vitro co-culture models utilize immortalized cell lines with different biological backgrounds, which may not accurately represent the cellular milieu or interactions of the lung. We differentiated human iPSCs into 3D lung organoids (containing both epithelium and mesenchyme), endothelial cells, and macrophages. These were co-cultured in an air-liquid interface (ALI) format to form an epithelial/mesenchymal apical barrier invested with macrophages and a basolateral endothelial barrier (iAirway). iPSC-derived iAirways showed a reduction in barrier integrity in response to infection with respiratory viruses and cigarette toxins. This multi-lineage lung co-culture system provides a platform for studying cellular interactions, signaling pathways, and molecular mechanisms underlying lung development, homeostasis, and disease progression. iAirways closely mimic human physiology and cellular interactions, can be generated from patient-derived iPSC's, and can be customized to include different cell types of the airway. Overall, iPSC-derived iAirway models offer a versatile and powerful tool for studying barrier integrity to better understand genetic drivers for disease, pathogen response, immune regulation, and drug discovery or repurposing in vitro, with the potential to advance our understanding and treatment of airway diseases.
The blood-air barrier in the large airways includes the trachea, bronchi, and bronchioles. It plays a crucial role in maintaining respiratory health and is made up of the airway epithelium, basement membrane, blood vessels and endothelial cells, and immune cells. The primary epithelial cells in the airway encompass basal cells, club cells, ciliated cells, and goblet cells. Basal cells, acting as the stem cells of the airway epithelium, are multipotent progenitors with high proliferative and self-renewal capabilities, giving rise to mature airway epithelial cells1. Club cells are non-ciliated, secretory cells that contribute to the maintenance o....
This study protocol was approved by the Institutional Review Board of UCSD's Human Research Protections Program (181180). This protocol uses small molecules and growth factors to direct the differentiation of pluripotent stem cells into airway cells, endothelial cells, and macrophages. These cells are then co-cultured onto cell culture inserts and polarized in an air-liquid interface. The details of the reagents, consumables, and equipment used are listed in the Table of Materials. The media and buff.......
There are multiple stages at which the differentiation of iPSC-derived airway organoids, endothelial cells, immune cells, and co-cultures can be assessed as successfully completed. Differentiations can be performed in different iPSC lines, and this protocol has been tested in at least five different lines. The protocol does need to be adapted to every new iPSC line, specifically by modifying and optimizing the seeding density.
The successful yield of iPSC-derived airway organoids can be assess.......
The development and implementation of a model of the blood-air barrier in the large airways for studying viral infections and other toxins require meticulous attention to detail to ensure the successful differentiation and function of the various cell types involved. This discussion will address key factors for successful differentiation, potential challenges, alternative applications, and implications for studying human diseases.
To ensure a successful differentiation, attention to the type .......
This research was supported by CIRM (DISC2COVID19-12022).
....Name | Company | Catalog Number | Comments |
12 well plates | Corning | 3512 | |
12-well inserts, 0.4 µm, translucent | VWR | 10769-208 | |
2-mercaptoethanol | Sigma-Aldrich | M3148 | |
Accutase | Innovative Cell Tech | AT104 | |
Activin A | R&D Systems | 338-AC | |
All-trans retinoic acid (RA)Â | Sigma-Aldrich | R2625 | |
ascorbic acid | Sigma | A4544 | |
B27 without retinoic acid | ThermoFisher | 12587010 | |
BMP4Â | R&D Systems | 314-BP/CF | |
Bovine serum albumin (BSA) Fraction V, 7.5% solution | Gibco | 15260-037 | |
Br-cAMP | Sigma-Aldrich | B5386 | |
CD 14 (FITC) | BioLegend | 982502 | |
CD 31 PECAM-1(APC) | R&D System | FAB3567A | |
CD 45 (PE) | BD Biosciences | 560975 | |
CD 68 (PE) | BioLegend | 33808 | |
CHIR99021Â | Abcam | ab120890 | |
CPM | Fujifilm | 014-27501 | |
Dexamethasone | Sigma-Aldrich | D4902 | |
Dispase | StemCellTech | 7913 | |
DMEM/F12Â | Gibco | 10565042 | |
Dorsomorphin | R&D Systems | 3093 | |
E-CAD/CD 324 (APC) | BioLegend | 324107 | |
EGF | R&D Systems | 236-EG | |
EGM2 Medium | Lonza | CC-3162 | |
EPCAM/CD 326 (APC) | BioLegend | 324212 | |
FBSÂ | Gibco | 10082139 | |
FGF10 | R&D Systems | 345-FG/CF | |
FGF7 | R&D Systems | 251-KG/CF | |
Fibronectin | Fisher | 356008 | |
Forskolin | Abcam | ab120058 | |
Glutamax | Life Technologies | 35050061 | |
Ham’s F12 | Invitrogen | 11765-054 | |
HEPES | Gibco | 15630-080 | |
IBMX (3-Isobtyl-1-methylxanthine) | Sigma-Aldrich | I5879 | |
IL-3 | Peprotech | 200-03 | |
Iscove’s Modified Dulbecco’s Medium (IMDM) + Glutamax | Invitrogen | 31980030 | |
Knockout Serum Replacement (KSR) | Life Technologies | 10828028 | |
Matrigel | Corning | 354230 | |
M-CSF | Peprotech | 300-25 | |
Monothioglycerol | Sigma | M6145 | |
mTeSR plus Kit (10/case) | Stem Cell Tech | 5825 | |
N2Â | ThermoFisher | 17502048 | |
NEAA | Life Technologies | 11140050 | |
PBS | Gibco | 10010023 | |
Pen/strep | Lonza | 17-602F | |
ReleSR | Stem Cell Tech | 5872 | |
RPMI1640 + Glutamax | Life Technologies | 12633012 | |
SB431542Â | R&D Systems | 1614 | |
SCF | PeproTech | 300-07 | |
SMA | Invitrogen | 50-9760-80 | |
STEMdiff APEL 2 Medium | STEMCELL Technologies | 5275 | |
TrypLE Express | Gibco | 12605-028 | |
VEGF165 | Preprotech | 100-20 | |
Vimentin | Cell Signaling | 5741S | |
Y-27632 (Rock Inhibitor)Â | R&D Systems | 1254/1 | |
ZO-1 | Invitrogen | 339100 |
Explore More Articles
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved